Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... [Yahoo! Finance]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024